NasdaqCM:VSTMBiotechs
Verastem (VSTM) Advances KRAS G12D Program—Could Early-Stage Data Redefine Its Oncology Roadmap?
Earlier this week, Verastem Oncology announced promising preliminary data from the Phase 1/2a clinical trial of VS-7375, an oral KRAS G12D inhibitor, in patients with advanced KRAS G12D mutant solid tumors, along with the initiation of a combination cohort with cetuximab.
These findings are significant, as there are currently no FDA-approved therapies specifically targeting KRAS G12D mutations in cancer, addressing a critical gap for patients with limited treatment options.
We'll explore how...